For patients with acute lymphoblastic leukaemia (ALL) carrying the Philadelphia chromosome and whose disease relapsed after allogeneic haematopoietic stem cell transplantation (HCT), the two-year overall survival rate has nearly doubled from the period between 2000 and 2004 to the period between 2015 and 2019.
The journal in which the study was published was Clinical Cancer Research a journal of the American Association for Cancer Research.
Ali Bazarbachi, MD, PhD, professor of medicine, associate dean for basic research, and director of the Bone Marrow Transplantation Program at the American University of Beirut, is the first and corresponding author.
ALL is an aggressive haematological malignancy. The presence of the Philadelphia chromosome (Ph+), a recurrent genetic alteration found in approximately 30 percent of adult ALL cases, is associated with a worse prognosis.
Allogeneic HCT is a procedure in which blood stem cells are transferred from a healthy donor to a patient who has received treatment with radiation or high doses of chemotherapy to kill the leukaemic cells. HCT is considered a potentially curative option for Ph+ ALL patients, especially those with persistent minimal residual disease (MRD), caused by a very small number of cancer cells that remain in the body after treatment.
Unfortunately, in some cases, the residual leukaemic cells can escape the anticancer immune response induced by the transplanted immune cells and proliferate. Disease relapse after transplant is common and remains the main cause of allogeneic HCT failure.
However, in recent years, new interventions aimed at reducing the risk of post-transplant relapse in Ph+ ALL patients have been developed, and new therapeutic strategies have become available for the management of post-transplant relapse, including newer-generation tyrosine kinase inhibitors, and immunotherapy such as blinatumomab (Blincyto), inotuzumab ozogamicin (Besponsa), and CAR-T cell therapy.
In addition, due to higher donor availability and a progressive increase in the use of matched unrelated donors, second allogeneic HCT as salvage therapy is also an option.
To assess the most recent trends in survival after post-HCT relapse, Bazarbachi and colleagues within the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT) conducted a retrospective, registry-based, multicenter study that included 899 adult patients with relapsed Ph+ ALL after allogeneic HCT over a period of 20 years (from 2000 to 2019).
The authors found a significant improvement in the two-year overall survival (OS) after relapse, which rose from 27.8 percent in patients who relapsed between 2000 and 2004 to 54.8 percent in those who relapsed between 2015 and 2019. The investigators also observed that survival increased with the length of time between HCT and relapse.
Notably, the survival improvement was observed despite a significant increase in patient age at the time of relapse (from 44 to 56 years).
A second allogenic HCT within two years after relapse was performed in 13.9 percent of patients, resulting in a two-year OS from the date of the second transplant of 35.9 percent, with a progressive decrease in the two-year relapse incidence from the date of the second transplant (74 percent in the 2000-2004 period and 33 percent in the 2015-2018 period.)
“In the subset of ALL patients carrying the Philadelphia chromosome, post-transplant relapse occurs in up to 30 percent of the cases, and in earlier studies, long-term survival was dismal,” said Bazarbachi. “However, several new therapeutic strategies have been recently approved for these patients, therefore it was important to study and compare the clinical outcomes between different time periods in the past 20 years.”
According to the authors, the observed increase in patient age at the time of relapse makes the findings even more impressive because, typically, longer survival is associated with younger age at the time of relapse. “This effect is likely due to the greater efficacy of the novel targeted therapies,” commented Bazarbachi.
“Our study represents the largest analysis to date assessing the outcomes and characteristics of patients with relapsed Ph+ ALL after allogeneic HCT, and our findings proved that the survival of these patients has significantly improved over time,” added Bazarbachi. “These large-scale real-world data can serve as a benchmark for future studies in this setting.”
According to the authors, one limitation of this retrospective study is the lack of detailed information on the treatment of post-transplant relapse and its impact on survival improvement, which remains to be investigated.
This is a registry study by the Acute Leukemia Working Party of the EBMT. No direct funding was reported. The authors declare no conflicts of interest.